近日,长风药业(2652.HK)迎来两项关键研发里程碑:其自主研发的微创介入肺减容装置完成首例受试者入组,标志着该微创介入治疗正式进入临床验证阶段;同时,公司面向肺纤维化的全球首创吸入创新药项目成功入选苏州市“关键核心技术攻关”项目,获得政府立项支持。长风药业在呼吸系统疾病治疗领域的综合布局超乎了公众原先对于公司的固有刻板印象。在呼吸疾病治疗领域,重度肺气肿与特发性肺纤维化(IPF)均属于高负担、...
Source Link近日,长风药业(2652.HK)迎来两项关键研发里程碑:其自主研发的微创介入肺减容装置完成首例受试者入组,标志着该微创介入治疗正式进入临床验证阶段;同时,公司面向肺纤维化的全球首创吸入创新药项目成功入选苏州市“关键核心技术攻关”项目,获得政府立项支持。长风药业在呼吸系统疾病治疗领域的综合布局超乎了公众原先对于公司的固有刻板印象。在呼吸疾病治疗领域,重度肺气肿与特发性肺纤维化(IPF)均属于高负担、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.